V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004877 | 310010430 | 1.53 | 65.4 | Palliative (P) | 2013-10-23 | 2013-10-27 | Cyclophosphamide + Docetaxel | 02 | N | 310024334 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310004878 | 310002194 | 1.53 | 44.2 | Curative (C) | 2013-09-22 | 2013-09-22 | METHOTREXATE | 2 | N | 310024365 | IRINOTECAN + MDG |
| 310004879 | 310006918 | 1.78 | 85.5 | Curative (C) | 2013-12-27 | 2015-01-01 | Azacitidine | N | N | 310024367 | CISPLATIN + DACARBAZINE |
| 310004880 | 310006918 | 0 | 83.5 | Palliative (P) | 2016-01-03 | 2016-01-03 | DABRAFENIB | 2 | N | 310024367 | R-GEM-P |
| 310004881 | 310006918 | 1.79 | 99.7 | Curative (C) | 2017-09-17 | 2017-10-03 | Gemcitabine + Oxaliplatin | N | N | 310024367 | DOCETAXEL + GEMCITABINE |
| 310004882 | 310002195 | 1.73 | 71 | Curative (C) | 2013-05-06 | 2013-05-09 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 310024382 | IVADO |
| 310004883 | 310002196 | 1.75 | null | Curative (C) | 2015-11-26 | 2015-12-11 | ECarboX | 02 | null | 310024387 | DABRAFENIB + TRAMETINIB |
| 310004884 | 310002197 | 1.82 | 83.2 | Palliative (P) | 2017-06-22 | 2017-06-29 | DHAP | 2 | N | 310024393 | CETUXIMAB + RT |
| 310004885 | 310002198 | null | 88.1 | Palliative (P) | 2016-02-16 | 2016-03-09 | CVP R | N | Y | 310024401 | NIVOLUMAB |
| 310004886 | 310002199 | 1.71 | 95.6 | Disease modification (D) | 2017-07-10 | 2017-07-14 | DABRAFENIB + TRAMETINIB | 2 | N | 310024407 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 310004887 | 310002200 | 0 | 70.5 | Palliative (P) | 2015-04-07 | 2015-04-14 | Busulfan Oral | N | N | 310024415 | CAPECITABINE + CISPLATIN + RT |
| 310004888 | 310006919 | 1.82 | 70.3 | Curative (C) | 2013-03-05 | 2013-03-05 | Cyclophosphamide oral | N | N | 310024417 | ENZALUTAMIDE |
| 310004889 | 310006919 | 0 | 68.8 | Curative (C) | 2013-12-10 | 2013-12-11 | Bevacizumab + CAPECITABINE + OXALIPLATIN | 02 | null | 310024417 | CAPECITABINE + MITOMYCIN |
| 310004890 | 310002201 | null | 0 | Neo-adjuvant (N) | 2013-08-04 | 2013-08-21 | MITOMYCIN | 02 | N | 310024430 | DOCETAXEL |
| 310004891 | 310002202 | 1.83 | 83 | Palliative (P) | 2016-08-27 | 2016-09-11 | Doxorubicin + Olaratumab | N | N | 310024432 | DABRAFENIB |
| 310004892 | 310002203 | 1.8 | 82.3 | Adjuvant (A) | 2013-10-29 | 2013-10-30 | PEG INTERFERON | N | N | 310024435 | SUNITINIB |
| 310004893 | 310002203 | 1.69 | 81 | Curative (C) | 2015-05-11 | 2015-05-11 | Cyclophosphamide High Dose | 02 | N | 310024435 | TEMOZOLOMIDE |
| 310004894 | 310002203 | 1.48 | 41 | Curative (C) | 2014-06-23 | 2014-06-24 | Cyclophosphamide Weekly PO | N | N | 310024435 | EC |
| 310004895 | 310002204 | 1.59 | 58 | null | 2016-10-20 | 2016-10-22 | CYCLOPHOSPHAMIDE | 2 | N | 310024441 | BEVACIZUMAB + TEMOZOLOMIDE |
| 310004896 | 310006921 | null | 65 | Palliative (P) | 2015-10-12 | 2015-11-08 | CETUXIMAB + RT | N | N | 310024451 | CYCLOPHOSPHAMIDE |
| 310004897 | 310002205 | null | null | Curative (C) | 2016-01-05 | 2016-01-08 | Cetuximab + Radiotherapy Load | 2 | N | 310024458 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 310004898 | 310002205 | 0 | 0 | Disease modification (D) | null | 2015-11-22 | Bevacizumab 7.5mg/kg | N | N | 310024458 | CARBOPLATIN + LIPOSOMAL DOX |
| 310004899 | 310009231 | 1.65 | 68 | Neo-adjuvant (N) | 2013-03-23 | 2014-06-13 | Bevacizumab + Oxaliplatin +MdG | N | N | 310024462 | RMS 2005 TRIAL |
| 310004900 | 310002206 | null | 54.4 | Palliative (P) | 2018-06-09 | 2018-06-10 | IVE | 2 | N | 310024468 | CYCLOPHOSPHAMIDE |
| 310004901 | 310002206 | 1.6 | 62.1 | Palliative (P) | 2014-11-03 | 2014-11-11 | ECHELON-2 TRIAL | 02 | null | 310024468 | BEVACIZUMAB |
| 310004902 | 310002207 | null | 0 | Disease modification (D) | null | 2016-04-01 | Cetuximab + Oxaliplatin + MdG Load | N | N | 310024481 | DOXORUBICIN + OLARATUMAB |
| 310004903 | 310002208 | 1.68 | 46.9 | null | 2016-03-23 | 2016-04-10 | Doxorubicin + Olaratumab | null | null | 310024494 | IFOSFAMIDE |
| 310004904 | 310006924 | null | 78.3 | null | 2013-12-04 | 2013-12-17 | MITOMYCIN | null | N | 310024498 | CYCLOPHOSPHAMIDE |
| 310004905 | 310009232 | 1.8 | 65 | Palliative (P) | 2013-11-03 | 2014-11-09 | Pemetrexed | 2 | N | 310024502 | ENZALUTAMIDE |
| 310004907 | 310002210 | 1.62 | 110.4 | Neo-adjuvant (N) | 2013-10-26 | 2013-10-29 | LANREOTIDE | N | N | 310024524 | METHOTREXATE |
| 310004908 | 310002211 | 0 | 62.1 | Palliative (P) | 2014-11-02 | 2014-11-11 | IVE | N | N | 310024529 | CARBOPLATIN + VINORELBINE |
| 310004909 | 310002212 | 1.63 | null | Palliative (P) | 2015-12-12 | 2016-01-03 | ICON8B TRIAL | 2 | N | 310024532 | CHLVPP |
| 310004910 | 310002213 | 1.68 | 45 | Palliative (P) | 2014-03-23 | 2014-03-25 | IVE | N | N | 310024541 | BEP |
| 310004911 | 310002214 | 1.73 | 0 | Palliative (P) | 2014-11-14 | 2014-11-14 | DABRAFENIB | N | N | 310024542 | CETUXIMAB + RT |
| 310004912 | 310002214 | 1.78 | 91.9 | Palliative (P) | 2017-05-09 | 2017-05-09 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | 310024542 | ENZALUTAMIDE |
| 310004913 | 310002215 | null | 0 | Palliative (P) | 2018-01-11 | 2018-01-12 | METHOTREXATE | 2 | N | 310024547 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 310004916 | 310002217 | 1.7 | 70.3 | Palliative (P) | 2018-02-18 | 2018-04-01 | Epirubicin (weekly) | N | N | 310024563 | VEDEX |
| 310004917 | 310002218 | null | null | Not known (9) | 2015-08-08 | 2015-08-19 | IVE | N | N | 310024564 | EPIRUBICIN |
| 310004918 | 310002218 | 1.48 | 87.2 | Palliative (P) | 2014-08-01 | 2014-09-11 | Bevacizumab 7.5mg/kg | N | N | 310024564 | INTERFERON |
| 310004919 | 310002219 | 1.96 | null | Curative (C) | 2013-12-18 | 2013-12-18 | EP | Y | N | 310024573 | CETUXIMAB |
| 310004920 | 310006928 | 1.68 | null | Palliative (P) | 2016-01-04 | 2016-01-19 | MTX HD + PROCARBAZINE + VINCRISTINE | N | N | 310024576 | ETOPOSIDE |
| 310004921 | 310002220 | 1.62 | 0 | Palliative (P) | null | 2018-05-23 | Sunitinib | 02 | N | 310024581 | R-EPOCH |
| 310004922 | 310002221 | 1.7 | null | Neo-adjuvant (N) | 2014-08-16 | 2014-09-23 | PEG INTERFERON | 02 | N | 310024582 | ALEMTUZUMAB |
| 310004923 | 310002222 | 1.59 | 83 | Palliative (P) | 2017-03-15 | 2017-02-22 | Pazopanib | N | null | 310024586 | ECF |
| 310004924 | 310002223 | null | 49.2 | Palliative (P) | 2014-12-10 | 2014-12-22 | DABRAFENIB | 2 | N | 310024588 | CETUXIMAB |
| 310004926 | 310002225 | 1.9 | 79.5 | Curative (C) | 2017-06-04 | 2017-06-04 | LANREOTIDE | Y | N | 310024602 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 310004927 | 310002226 | 1.65 | 53.6 | Curative (C) | 2017-03-27 | 2017-04-10 | Irinotecan + Modified De Gramont | N | N | 310024606 | DABRAFENIB |
| 310004928 | 310002227 | 1.67 | 90 | Palliative (P) | 2015-03-15 | 2015-03-26 | Trastuzumab Subcutaneous | 02 | N | 310024612 | CARBOPLATIN + LIPOSOMAL DOX |
| 310004929 | 310002228 | 1.6 | -1 | null | 2018-01-17 | 2018-01-30 | CARBO + ETOPOSIDE + VINCRISTINE | 02 | N | 310024631 | INTERFERON |
| 310004930 | 310002228 | 1.79 | 86.6 | Palliative (P) | 2018-04-07 | 2018-04-08 | Chlorambucil | 02 | N | 310024631 | POUT TRIAL |